WhereDaily News: PURE Completes Phase One Technology Transfer for Expanded Production -- Intercon SDC Facility Online

SAN DIEGO, CA--(Marketwired - Jan 23, 2014) - PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced it has completed the first phase of the SDC technology transfer to its collaboration partner, Intercon Chemical Company (ICC). The first phase consists of the partial transfer of PURE's unique and proprietary SDC manufacturing process into a new and dedicated production facility at ICC's St. Louis manufacturing location.

Home | Contact Us | Advertise
Tour Operator Signup
Travel Agent Signup
Press Room | Link Partners
Legal | Privacy